Jonathan Kay to Anti-Citrullinated Protein Antibodies
This is a "connection" page, showing publications Jonathan Kay has written about Anti-Citrullinated Protein Antibodies.
Connection Strength
0.374
-
Deane KD, Striebich CC, Feser ML, O'Dell JR, James JA, Sparks JA, Davis JM, Graf J, McMahon MA, Solow EB, Forbess LJ, Tiliakos A, Schiopu E, Danila MI, Horowitz DL, Kay J, Strickland CD, Guthridge JM, Arriens C, Grossman JM, Kristen Demoruelle M, Bemis EA, Frazer-Abel A, Fleischer CL, Fox DA, Mikuls TR, Greenleaf M, York K, Walker S, Keyes-Elstein L, Byron M, Fedler J, Goldmuntz EA, Holers VM. A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2026 04; 78(4):809-820.
Score: 0.239
-
Baecklund E, Backlin C, Rönnelid J, Toes R, Huizinga T, Åhlin E, Askling J, Hochberg FH, Klareskog L, Kay J, Smedby KE. Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scand J Rheumatol. 2018 07; 47(4):270-275.
Score: 0.136